Cellceutix Corp. (CTIX.OB) Signs Agreement with Formatech for Kevetrin™
Cellceutix Corp. has signed an agreement with Formatech to formulate Kevetrin for a Phase 1 study as issued in a press release this morning at 7:30 am EST. Formatech, based in Andover, Massachusetts, was established in 1993 and provides contract services for their clients’ product development and manufacturing challenges. Fomatech has achieved excellent results in developing biotherapeutic products. This agreement helps Cellceutix stay on course with the future Investigational New Drug (IND) filing for Kevetrin. Kevetrin, Cellceutix’s lead product, is a drug in developmental processes to treat drug resistant cancers. Cellceutix’s Chief Scientific Officer, Dr. Krishna Menon, MCA, PhD, VMD,…